Forbion Raised €2.3 Billion for Biotech Investing
The firm secured capital to back 30 new portfolio companies as market funding remains limited.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Do you believe private venture capital investment effectively accelerates the development of necessary medical treatments?
Forbion has announced the completion of a €2.3 billion fundraising round, bringing the firm's total assets under management to approximately €7.5 billion. The capital was secured through two new funds, Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII.
Why it matters
This capital raise provides a liquidity injection for biotech startups during a period of market-wide funding shortages. It enables Forbion to scale its investment strategy across Europe and North America to support early-stage development.
The firm raised a total of €2.3 billion, equivalent to $2.6 billion, to finance approximately 30 high-potential portfolio companies. This follows a historical track record of financing 142 companies since the firm's inception.
The players
Forbion
A venture capital firm based in Naarden, The Netherlands, specializing in life sciences and biotech investments across Europe and North America.
Eli Lilly and Company
A major pharmaceutical developer that participated in the funding round, contributing its industry perspective to the firm's investment strategy.
The details
Forbion secures capital by aggregating funds from institutional investors including MN, PGGM, KfW Capital, the Kauffman Foundation, and Eli Lilly and Company. The firm acts as a venture capital investor, selecting life sciences companies to provide financing and operational support. Historically, this model has resulted in the delivery of 21 approved medical products that have impacted 1.6 million patients.
Timeline
October 6, 2026: Forbion announced the completion of the €2.3 billion fundraise.
The Tech Race
This raise positions Forbion to maintain its influence in the competitive European and North American life sciences landscape. It follows a multi-year trend where venture firms consolidate assets to sustain high-potential pipelines in a constrained financing environment.
The capital will be deployed into approximately 30 portfolio companies over the coming months, likely accelerating the development timeline for new medical products. Industry participants should monitor Forbion's deal announcements to identify which specific therapeutic areas receive this influx of financing.
The takeaway
Large-scale venture capital raises continue to be the primary engine for bridging the gap between bench research and clinical availability. Watch for the first investments from these funds, as they will indicate which sub-sectors of biotechnology the firm believes hold the most promise for patient impact.
Further reading
For more on capital trends in this field, see our latest coverage of Biotech.
Live Poll
Do you believe private venture capital investment effectively accelerates the development of necessary medical treatments?
